

CA 15-3 Assay

Order Name: **CA15-3**
 Test Number: 2024000
 Revision Date: 10/28/2025

TEST NAME	METHODOLOGY	LOINC CODE
CA 15-3 Assay	<u>Chemiluminescence Assay</u>	6875-9

SPECIMEN REQUIREMENTS

Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	2mL (1mL)	Serum	Clot Activator SST	Refrigerated
Alternate 1	2mL (1mL)	Plasma	Lithium Heparin PST (Light Green Top)	Refrigerated
Instructions	Separate from cells within 2 hours after collection. Stability: Ambient 1 day. Refrigerated 7 days. Frozen > 7 days.			

GENERAL INFORMATION

Testing Schedule	Mon - Fri
Expected TAT	1-3 days
Clinical Use	Measurements of CA 15-3 in women with treated carcinoma of the breast may be useful for predicting early recurrence. The FDA has approved CA 15-3 for serial testing in women with prior stage II or III breast cancer who are clinically free of disease.
Notes	Testing performed via Abbott Alinity Immunoassay method. Results obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy.
CPT Code(s)	86300
Service Provided By	 labcorp Oklahoma, Inc.